Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.75  1.15  29.49%   
About 54% of Lisata Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are impartial. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a month ago at gurufocus.com         
Neurocrine Biosciences Announces Commercial Availability of CREN
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Avidity Biosciences, Inc. Insider Sells 831,500.00 in Stock
news
over a month ago at gurufocus.com         
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Gurufocus Stories at Macroaxis
over a month ago at investing.com         
Assembly Biosciences strikes amended deal with Gilead
Investing News at Macroaxis
over a month ago at prnewswire.com         
Alafair Biosciences Celebrates Over 22,000 Implants of VersaWrap Hydrogel Sheet in Patients
prnewswire News
over a month ago at businesswire.com         
Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therap...
businesswire News
over a month ago at finance.yahoo.com         
Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive Officer
Yahoo News
over a month ago at gurufocus.com         
Assembly Biosciences Announces 30.1 Million Equity Investment and Accelerated Funding from ...
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Yahoo News
over a month ago at thelincolnianonline.com         
HC Wainwright Initiates Coverage on Harmony Biosciences
news
over a month ago at thelincolnianonline.com         
Castle Biosciences, Inc. Sees Significant Growth in Short Interest
news
over a month ago at gurufocus.com         
Xenetic Biosciences, Inc. Releases Virtual Investor What This Means Segment
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Contrasting VectivBio and Senti Biosciences
news
over a month ago at benzinga.com         
Why Forte Biosciences Stock Is Trading Lower
benzinga news
over a month ago at gurufocus.com         
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the ...
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Keymed Biosciences gibt die Zulassung von Stapokibart fr die Behandlung von chronischer Rhinosinusitis mit Nasenpolyposis bekannt
12/24/2024
2
Shareholders that lost money on Caribou Biosciences, Inc. ...
12/31/2024
3
Avidity Biosciences Announces Inducement Grants for New CTO
01/08/2025
4
Disposition of 2131 shares by James Nisco of Lisata Therapeutics at 3.8 subject to Rule 16b-3
01/13/2025
5
Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates shares rise
01/14/2025
6
Colossal Biosciences takes de-extinction maintstream
01/15/2025
7
Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China
01/16/2025
8
Junshi Biosciences Announces Toripalimabs Approval in Australia
01/17/2025

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk